about
Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogenMicroRNA fingerprints during human megakaryocytopoiesisMicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3BPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyEpigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemiaMicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemiaAcute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic InsightsMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaFLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogeneticsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasTargeting epigenetic changes in acute myeloid leukemia.Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.Methods for high-throughput MethylCap-Seq data analysis.Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemiaPrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data.Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaGAS6 expression identifies high-risk adult AML patients: potential implications for therapyClinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantationPhase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cellsSp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
P50
Q24300234-2EE2D770-24BE-4522-B381-33D0B1366712Q24546361-2C6F44DE-468A-414B-9E70-ACEF91894D34Q24564757-03587EDB-C487-492F-BEB5-4A61C0EF72B7Q24643738-E95F40CA-AEB0-4AD9-8C3E-3B0FC4BE6A2EQ24652017-F047F178-264D-47A8-8C70-B992E1D56E01Q24655915-06A7217F-33F9-4757-9ADA-0DEC197CAD14Q26753035-529E7BF1-486C-464D-A3EA-7FC4AD7E8E52Q26998811-06A62A44-B291-4BF2-92C7-B95EBD005EE1Q27851415-9F94FCC0-C28C-41F5-AF3D-D8071794EFD3Q27851436-661C71A2-C3E6-4BA8-8A25-13055C5B889CQ27851545-6960CACE-5919-4E21-9EEC-26FF30A30C2AQ27851621-2C688223-4DB9-442D-ABF6-49F39FAB3F2EQ27851679-0CE695D8-35C9-426E-8465-ED1EFEB38796Q27851713-BF39AFC7-4C07-47E4-886F-C112C3BE5CB3Q27851839-EFCA33EA-9555-4112-B281-58FC8FA33C59Q28298765-862037FF-1AE1-414E-95BE-EAF421254F1EQ28301344-A16DD715-1EB8-4E55-BFC5-9BBD07BF6C57Q28594733-B23D97C5-EEBD-4A91-AD7C-3CC2D2A7632EQ30353043-ED482E39-7BDF-4843-9721-DEE03FCE9001Q30449092-866278F4-24CC-4A68-9337-5FA201299E0BQ30496174-D818A79A-0CE7-45BE-9038-69391679FA49Q30576735-021FE233-4F9C-4F9E-887C-14317CE7AB4DQ30622245-DF025CB4-EF5F-41A0-975B-2FC211223B04Q30846971-E68CC2B6-5FF2-47AD-8F04-72C12F2DE3F7Q33272682-E5C1D0FE-0272-4B59-8360-054510B7E644Q33389485-6C65611A-837F-49E7-86D3-B0EE77F63952Q33418791-F5826ABF-007B-475A-B0B6-DE4D3374858BQ33558183-524FACE9-E2E8-477F-A25C-08C6DD349F9AQ33597507-F801BC44-1516-4B00-ACF8-1FDF38B8B3A5Q33623126-411064B4-0050-43BA-881A-4A8DA2CAD8EEQ33717707-C2F211B1-5F82-410D-BDAE-76433BFA612CQ33841988-E8C624D5-F7DF-474E-AB83-4BFC56B1709AQ33842055-E59D6494-D31C-4199-AE32-8296710993BBQ33897586-E703C4CB-516E-42FB-A33B-C459C003B51EQ33910076-386A643E-7E7A-4167-8B04-845DAE6E4DF5Q33952759-7E9DFD3B-F2F6-4B3A-A062-7D0DBEA20AA1Q33999386-6456DAE9-8963-4EC7-9063-D4B9D23676F5Q34047867-80323972-06A6-41CE-87C7-F9F5625EDBC6Q34048276-1A046145-56CB-4191-A785-350E328A3407Q34052614-EF5D36A1-8ED5-407F-91B4-74E9BBE484CC
P50
name
Guido Marcucci
@ast
Guido Marcucci
@en
Guido Marcucci
@nl
type
label
Guido Marcucci
@ast
Guido Marcucci
@en
Guido Marcucci
@nl
prefLabel
Guido Marcucci
@ast
Guido Marcucci
@en
Guido Marcucci
@nl